Skip to main content
2024 PharmSci 360 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Listen Now

Manufacturing & Analytical Characterization
Partner Presentation

Oligo mapping of Large RNA Therapeutics by Novel Enzyme Specificities

Monday, October 21, 2024
11:00 AM – 12:00 PM MT
Location:360 Stage #2, Exhibit Hall

Sponsored By 
Manufacturing and Analytical Characterization Partner Presentation-Manufacturing & Bioprocessing

Description: Advancements in large RNA therapeutics command the development of new technologies to characterize mRNA, sgRNA, and associated impurities. Available enzymes and data analysis workflows are inadequate for rapid and sensitive characterization. Complementary cleavage specificities are needed to fill the sequence coverage gap by available RNases. Tunable dinucleotide specific enzymes generating shorter and longer digestion products and streamlined informatics from Waters enable accurate sequence confirmation with high efficiency and confidence to ensure integrity in a single LC-MS run.

Learning Objectives:

  • How to accelerate the development of CRISPR sgRNA and mRNA therapeutics with the introduction of novel tools to lower the barrier for thorough characterization and monitor product quality using LC-MS.
  • Discover how new RNases provide the ability to generate more unique digestion products, provide full sequence coverage and modifications tied to potency and efficacy in a single LC-MS experiment.
  • Comprehensive solutions to streamline the confident confirmation of oligonucleotide sequence and robust oligo mapping workflows for convenient routine RNA analysis in a GMP compliant environment.